跳至主要内容
临床试验/NCT01187667
NCT01187667已完成不适用

Evaluation Study of a Delirium Prevention Policy Using Prophylactic Haloperidol in Critically Ill Patients With a High Risk for Delirium

Radboud University Medical Center1 个研究点 分布在 1 个国家目标入组 650 人开始时间: 2010年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
650
试验地点
1
主要终点
Delirium incidence

研究概览

简要总结

Haloperidol is prescribed in high risk ICU patients concerning delirium (50% or more chance to develop delirium detected with the delirium prediction model PRE-DELIRIC, or patients with history of dementia or alcohol abuse)since the delirium protocol is changed and haloperidol is added as a prevention treatment we are gathering information what the effect is on several aspects of delirium

详细描述

Measurement the effect of haloperidol as delirium preventive intervention. Determining effect on:

  • delirium incidence in the ICU - different subtypes of delirium - delirium free days in 28 days - days on the ventilator - length of stay on the ICU and In-Hospital - 28-day mortality - incidence of unexpected removal of tubes, and effect between different groups of patients. Safety of haloperidol concerning QT-time, extrapyramidal symptoms.

Data are compared with the data of a historical cohort

研究设计

研究类型
Observational
观察模型
Case Control

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients With Predicted Delirium Chance of >50% or history of dementia or alcohol abuse and treated with haloperidol

排除标准

  • CAM-ICU is Not Applicable
  • Patients Admitted 24hours or Shorter on the ICU, Patients Who Are Delirious Within 24 Hours After ICU Admission
  • patients whereby haloperidol is contra-indicated

结局指标

主要结局

Delirium incidence

时间窗: one year

Delirium is diagnosed as minimal one positive CAM-ICU screening during complete ICU admission. Incidence rate is compared with historical cohort data

次要结局

  • duration of delirium days on mechanical ventilator Length of stay in the ICU and in-hospital in-hospital mortality incidence of unplanned removal of tube incidence of delirium subtypes(one year)
  • Effect haloperidol on biomarkers(one year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mark van den Boogaard

PhD

Radboud University Medical Center

研究点 (1)

Loading locations...

相似试验